EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

All-trans retinoic acid combined with the VAH regimen for EVI1-positive acute myeloid leukemia: a case report with a brief literature review

Yingxin Zhao, Hongxia Wang, Jiaxin Lv, Pei Pei, Zhengyang Zhang, Bei Zhang, Zhixin Pei, Junjun Bai, Jingjing Gu, Huimin Wu, Fei Wang, Yi Zhang und 1 weitere

Frontiers in Oncology · 15.04.2026 · 16

DOI: 10.3389/fonc.2026.1790087 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Frontiers in Oncology, online erschienen am 15.04.2026. Verfasst von Yingxin Zhao und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Jiaozuo People's Hospital, Jiaozuo, Henan, China. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

EVI1 positivity is a well-recognized high-risk factor in acute myeloid leukemia (AML), typically characterized by complex molecular genetic abnormalities, suboptimal responses to conventional chemotherapy, and a poor prognosis. We report a case of a 42-year-old patient with EVI1-positive AML harboring the MLL-AF6 fusion gene, who failed to achieve remission after undergoing standard “IA” induction therapy and was then treated with VAH (venetoclax, azacitidine, and homoharringtonine) consolidation chemotherapy. The patient subsequently received all-trans retinoic acid (ATRA) (20 mg twice daily, administered orally) and achieved complete remission with incomplete hematologic recovery (CRh) after 24 days, accompanied by a marked reduction in EVI1 expression relative to baseline levels. Following this, consolidation therapy consisting of one cycle of “VAH plus ATRA” led to complete remission (CR). This case suggests that the combination of ATRA with the VAH regimen may demonstrate promising efficacy and an acceptable safety profile in patients with EVI1-positive AML who are refractory to conventional chemotherapy. However, further clinical studies are required to confirm its wider applicability.

Schlagwörter

Stichwörter der Autor:innen

EVI1VAH regimenacute myeloid leukemiaall-trans retinoic acidrefractory leukemia

Autor:innen und Institutionen

  • Department of Hematology, Jiaozuo People's Hospital, Jiaozuo, Henan, China.
  • Laboratory of Hematological Diseases, Jiaozuo People's Hospital, Jiaozuo, Henan, China.
  • Department of Rehabilitation, Jiaozuo People's Hospital, Jiaozuo, Henan, China.
  • Department of Clinical Pharmacy, Jiaozuo People's Hospital, Jiaozuo, Henan, China.

Zitieren

APA

Zhao, Y., Wang, H., Lv, J., Pei, P., Zhang, Z., Zhang, B., Pei, Z., Bai, J., Gu, J., Wu, H., Wang, F., Zhang, Y., & Song, Q. (2026). All-trans retinoic acid combined with the VAH regimen for EVI1-positive acute myeloid leukemia: a case report with a brief literature review. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1790087

Vancouver

Zhao Y, Wang H, Lv J, Pei P, Zhang Z, Zhang B, et al. All-trans retinoic acid combined with the VAH regimen for EVI1-positive acute myeloid leukemia: a case report with a brief literature review. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1790087

BibTeX
@article{Zhao2026,
  author = {Zhao, Yingxin and Wang, Hongxia and Lv, Jiaxin and Pei, Pei and Zhang, Zhengyang and Zhang, Bei and Pei, Zhixin and Bai, Junjun and Gu, Jingjing and Wu, Huimin and Wang, Fei and Zhang, Yi and Song, Qinglin},
  title = {All-trans retinoic acid combined with the VAH regimen for EVI1-positive acute myeloid leukemia: a case report with a brief literature review},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1790087}
}
Kostenlos starten →